Advances in™ Bipolar Depression: Expert Strategies to Optimize Patient Outcomes in Depressive Episodes

Released On
November 2, 2021

Expires On
November 2, 2022

Media Type
Internet

Completion Time
60 minutes

Specialty
Primary Care, Psychiatry

Topic(s)
Bipolar Disorder, Depression, Mood Disorders,

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

This activity is supported by educational grants from Intra-Cellular Therapies, Inc., and Sunovion Pharmaceuticals Inc.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — 1.0 Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This online educational activity is directed toward psychiatrists, specialty NPs and PAs, and primary care physicians engaged in the care of patients with bipolar depression.

Activity Overview

Bipolar disorder (BPD) is a lifelong, frequently recurring mood disorder characterized by treatment-resistant depressive episodes and cognitive decline that negatively impact functionality and quality of life in patients with the condition. Many pharmacological treatments for BPD adversely affect cognition, and those that are beneficial can be difficult to use. However, in recent years, new monotherapies and adjunct treatment options have emerged.

Learning Objectives

Upon completion of this activity, you should be better able to:

  • Identify the differential diagnoses for bipolar disorderE
  • Integrate current treatment recommendations into the care of patients with bipolar disorder
  • Evaluate data on new and emerging treatment options for bipolar disorder depressive symptoms
  • Discuss psychosocial concerns faced by patients with bipolar disorder and disease outcomes

 

Faculty

FACULTY_NAME

Christoph U Correll, MD

Professor, Psychiatry and Molecular Medicine
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Professor, Institute of Behavioral Science, Feinstein Institutes for Medical Research
Medical Director
Recognition and Prevention (RAP) Program, Department of Psychiatry
Zucker Hillside Hospital

FACULTY_NAME

Wendy L. Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP

Adult/Family Nurse Practitioner
Owner, Wright & Associates Family Healthcare
Concord and Amherst, New Hampshire

 

Physician Accreditation Statement

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

Disclosures of Conflicts of Interest

 

Christoph U Correll, MD

  • Grant Research Support: Janssen Pharmaceuticals, Takeda Pharmaceutical Company
  • Consultant: AbbVie Inc.; Acadia Pharmaceuticals Inc.; Alkermes; Allergan; Angelini Pharma; Aristo Pharma; Axsome Therapeutics; Darnitsa Pharmaceutical Company; Gedeon Richter; Hikma Pharmaceuticals; Intra-Cellular Therapies; Janssen/Johnson & Johnson; Karuna Therapeutics; LB Pharmaceuticals, Inc.; Lundbeck; MedAvante-ProPhase, Inc.; MedInCell; Medscape; Merck & Co, Inc.; Mitsubishi Tanabe Pharma Corporation; Mylan; Neurocrine Biosciences, Inc.; Noven Therapeutics LLC; Otsuka Pharmaceutical Co., Ltd.; Pfizer Inc.; Recordati; Relmada Therapeutics, Inc.; Rovi; Seqirus; Servier Laboratories; SK Life Science Inc; Sumitomo Dainippon Pharma; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals; Takeda; Teva Pharmaceutical Industries Ltd.; Viatris; Shareholder: LB Pharmaceuticals, Inc.
  • Other: Royalties from UpToDate, Inc.

 

Wendy L. Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP

  • Consultant: GSK - OA/Pain; Pfizer, Sanofi and Merck: Vaccines
  • Speaker’s Bureau: Pfifzer, Sanofi and Merck: Vaccines; AbbVie and Biohaven: Migraines

 

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Instructions for Participation and Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.
You may immediately download your certificate.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.